In the last trading session, 1.49 million shares of the Taysha Gene Therapies Inc (NASDAQ:TSHA) were traded, and its beta was 0.39. Most recently the company’s share price was $2.44, and it changed around $0.07 or 2.95% from the last close, which brings the market valuation of the company to $491.37M. TSHA currently trades at a discount to its 52-week high of $4.32, offering almost -77.05% off that amount. The share price’s 52-week low was $0.62, which indicates that the current value has risen by an impressive 74.59% since then. We note from Taysha Gene Therapies Inc’s average daily trading volume that its 3-month average coming to 2.69 million.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA has showed a green trend with a performance of 2.95% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 37.85% year-to-date, but still up 9.91% over the last five days. On the other hand, Taysha Gene Therapies Inc (NASDAQ:TSHA) is -37.60% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $21.4, which translates to bulls needing to increase their stock price by 88.6% from its current value. Analyst projections state that TSHA is forecast to be at a low of $7 and a high of $44.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Taysha Gene Therapies Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 46.11 percent over the past six months and at a 56.25% annual growth rate that is well above the industry average of 12.40%. The year-over-year growth rate is expected to be -28.00%, down from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 2.66M in revenue for the current quarter. 11 analysts expect Taysha Gene Therapies Inc to make 2.68M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.4M and 4.75M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 11.10%. Forecasts for the next quarter put sales growth at -43.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -137.69%.
TSHA Dividends
Taysha Gene Therapies Inc’s next quarterly earnings report is expected to be released in August.